Literature DB >> 7916523

Compliance with antipsychotic drug treatment: influence of side effects.

W W Fleischhacker1, U Meise, V Günther, M Kurz.   

Abstract

In addition to other factors such as type and duration of treatment, patient- and illness-related variables and other psychosocial features, side effects are known to exert a significant influence on the compliance with antipsychotic treatment. This has been demonstrated for extrapyramidal motor side effects and akathisia, sedation, weight gain and sexual dysfunctions. Other adverse events interfering with the patients' social roles also interfere with the patients' willingness to comply with treatment. It is important to acknowledge this not only in the acute treatment of schizophrenia but especially during maintenance and prophylactic treatment. Compliance can be considerably improved by a) adequately informing the patient about the risks and nature of side effects and b) by recognizing and treating side effects, since prevention of adverse events is not easily achieved. An underestimation of the influence of side effects on compliance will often lead to treatment failures that are erroneously attributed to treatment resistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916523

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  40 in total

1.  Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment.

Authors:  Kun-Po Chen; For-Wey Lung
Journal:  Psychiatr Q       Date:  2017-12

2.  Behavioral medicine interventions can improve the quality-of-life and health of persons with HIV disease.

Authors:  K J Sikkema; J A Kelly
Journal:  Ann Behav Med       Date:  1996-03

Review 3.  Review: treatment of schizophrenia. State of the art.

Authors:  H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

4.  Consumers' questions about antipsychotic medication: revealing safety concerns and the silent voices of young men.

Authors:  Rianne A Weersink; Katja Taxis; Treasure M McGuire; Mieke L van Driel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-12-30       Impact factor: 4.328

5.  Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.

Authors:  J J Miceli; K D Wilner; R A Hansen; A C Johnson; G Apseloff; N Gerber
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

Review 6.  Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.

Authors:  W W Fleischhacker; M Hummer
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

7.  Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Authors:  Martha Sajatovic; Jennifer Levin; Luis F Ramirez; David Y Hahn; Curtis Tatsuoka; Christopher S Bialko; Kristin A Cassidy; Edna Fuentes-Casiano; Tiffany D Williams
Journal:  J Clin Psychiatry       Date:  2013-12       Impact factor: 4.384

8.  Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Authors:  Allen W Nyhuis; Douglas E Faries; Haya Ascher-Svanum; Virginia L Stauffer; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2010-09-28       Impact factor: 3.630

9.  Sedation and disruption of maternal motivation underlie the disruptive effects of antipsychotic treatment on rat maternal behavior.

Authors:  Changjiu Zhao; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2008-11-17       Impact factor: 3.533

10.  Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity.

Authors:  Changjiu Zhao; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2012-08-31       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.